Filing Flows › Health Care › Spruce Biosciences (SPRB)
Spruce Biosciences (SPRB) earnings and revenue breakdown
Latest: Q4 2024 · 10-K filed Apr 15, 2025 · Spruce Biosciences (SPRB) Q4 2024 earnings results →
Q4 2024 Revenue down 76% year over year to $697K
Spruce Biosciences made $697K in Q4 2024 (-76% Y/Y). Operating margin n/m, net loss $23.6M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-K filed Apr 15, 2025.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $697K in Q4 2024, down 76% year over year and up 16% from the previous quarter.
Operating costs exceeded revenue by $24.1M, an operating margin of -3453.9%. Total costs grew 76% against a revenue fall of 76%. The fastest-growing cost line was Research & development (+93%). The quarter ended with a net loss of $23.6M, wider than the previous quarter's $8.7M loss.
Operating cash flow was −$20.7M. Non-cash charges added back $9K of depreciation and amortization and $1.0M of share-based compensation. Working capital and other items added $1.9M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q4 2024 | 10-K | Apr 15, 2025 | $697K | -76% | n/m | −$23.6M | −$20.7M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Spruce Biosciences
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. Spruce’s lead product candidate, tralesinidase alfa enzyme replacement therapy (TA-ERT), is in late-stage development for the treatment of mucopolysaccharidoses type IIIB (MPS IIIB), or Sanfilippo Syndrome Type B, a devastating pediatric neurodegenerative disorder for which there are no FDA-approved therapies. TA-ERT has received Breakthrough Therapy Designation, Rare Pediatric Disease Designation, Fast Track Designation and Orphan Drug Designation from the FDA, as well as Orphan Drug Designation in the European Union. To learn more, visit www.sprucebio.com and follow us on X , LinkedIn , Facebook and YouTube .
In its own words, from its 8-K, filed Aug 12, 2026.
Spruce Biosciences against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -76% against the peers' median +7%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| SPRB Spruce Biosciences | Q4 2024 | $697K | -76% | n/m |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Spruce Biosciences 10-K on SEC EDGAR · CIK 1683553 · Pharmaceutical Preparations
13F: who owns SPRB and who is buying
More on SPRB
History
Every quarter: Q4 2024 results